Plant · Scientific monograph
Scutellaria baicalensis
Baikal Skullcap / Chinese Skullcap
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Anti-inflammatory Research, Hepatoprotection Research, Neuroprotection Research, Anticancer Research
Research overview
Historical use
Scutellaria baicalensis (huang qin in traditional Chinese medicine) is one of the most important herbs in the Chinese pharmacopoeia, referenced in the Shennong Bencao Jing compiled approximately 200 CE, where it was classified as a superior-grade herb for treating fevers, dysentery, hypertension, and infections. For over 2,000 years it has been widely prescribed in Chinese clinical practice, included in classical formulas such as Huang Lian Jie Du Tang (inflammatory febrile diseases), Xiao Chai Hu Tang (liver and digestive conditions), and Yin Chiao San (common cold). Its Chinese name huang qin (yellow root) reflects the intensely yellow colour from flavone pigmentation.
Modern research context
Scutellaria baicalensis is among the most extensively researched TCM herbs in molecular pharmacology. A 2025 comprehensive review summarises evidence from clinical pilot studies for anti-inflammatory activity in rheumatoid arthritis and inflammatory bowel conditions [1]; these pilot studies are small and largely from Chinese clinical settings — they provide Level C evidence at most, with larger independent RCTs needed to confirm efficacy and generalisability. Hepatoprotective effects are documented: baicalin inhibits hepatic fibrosis markers and reduces liver enzyme elevation in clinical studies of hepatitis and fatty liver disease (Level C-B) [3]. Neuroprotective potential with anti-neuroinflammatory activity relevant to neurodegenerative diseases is supported by strong preclinical data and emerging translational evidence [5]. Antiviral activity against SARS-CoV-2 (primarily characterised in vitro via viral protease inhibition; no completed RCTs), influenza (in vitro and limited TCM multi-herb formula observational data), and enterovirus (primarily in vitro) has been described; dedicated clinical trial evidence for any specific antiviral indication remains preliminary. Anticancer applications are primarily at Level D-E (preclinical) for most tumour types. Clinical trial evidence overall remains Level B-C for most specific indications, with stronger pharmacological mechanistic support.
Adverse effects
Demonstrated acceptable tolerability in short-term clinical trials at standard doses (typically 4–8 weeks), with mild GI effects (nausea, diarrhoea) most commonly reported at higher doses; formal long-term safety data beyond this period from controlled trials are limited. The primary safety concern is hepatotoxicity from products of uncertain botanical identity. Case reports exist predominantly for North American Scutellaria lateriflora (aerial parts used, distinct from S. baicalensis root), not for verified S. baicalensis root preparations; hepatotoxicity in skullcap supplements is often attributed to adulteration with hepatotoxic Teucrium species (germander) — a documented risk in commercial skullcap products. Note: S. baicalensis (Baikal skullcap, root, huang qin) and S. lateriflora (American skullcap, aerial parts) are distinct species sharing a common name in the supplement market. Verified S. baicalensis root preparations have a more favourable safety profile. Antiplatelet activity warrants caution with anticoagulants. Mild GI effects (nausea, diarrhoea) occur with high doses.
Contraindications
Concurrent anticoagulant or antiplatelet therapy -- baicalein inhibits platelet aggregation; monitoring required. CYP2C9 substrates (warfarin, phenytoin, NSAIDs): CYP2C9 inhibition by baicalin may elevate plasma drug levels. Pregnancy -- insufficient safety data; traditional precaution. Pre-surgery: withdraw 2 weeks prior due to antiplatelet activity. Products of uncertain botanical identity -- adulteration risk with hepatotoxic Teucrium species is documented in commercial markets.
Clinical and phytochemical data
Used part
Root (radix -- dried peeled root, known as huang qin). Roots are standardized for baicalin content (typically 85-90% of total flavones).
Primary active compounds
Baicalin (baicalein-7-glucuronide, ~10-15% of dry root) -- primary flavonoid; anti-inflammatory, antiviral, neuroprotective
Baicalein (aglycone of baicalin) -- anti-inflammatory; 5-LOX and COX inhibitor; GABA-A modulator
Wogonin (5,7-dihydroxy-8-methoxyflavone) -- anticancer, anti-inflammatory, antiviral
Wogonoside (wogonin-7-glucuronide) -- anti-inflammatory
Oroxylin A (6-methoxybaicalein) -- neuroprotective, antitumour
Scutellarein and scutellarin (6-hydroxybaicalein derivatives) -- antioxidant, anti-inflammatory
Mechanism of action
Baicalin and baicalein are the primary pharmacologically active flavones. Anti-inflammatory activity involves direct inhibition of 5-lipoxygenase (5-LOX) and COX-2, blocking both leukotriene and prostaglandin synthesis pathways simultaneously -- an advantage over COX-only inhibitors [1, 2]. Baicalein inhibits NF-kB nuclear translocation by preventing IkBa phosphorylation, suppressing transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) [2]. Antiviral mechanisms include inhibition of viral RNA-dependent RNA polymerase and viral capsid assembly for several RNA viruses including SARS-CoV-2 [3]. Neuroprotective effects involve inhibition of microglial NLRP3 inflammasome activation and reduction of neuroinflammatory mediators in the CNS [5]. Baicalein acts as a positive allosteric modulator at GABA-A receptors (benzodiazepine-binding site), contributing to anxiolytic and sleep-promoting effects. Anticancer mechanisms in vitro involve activation of caspase-3/9-mediated apoptosis and VEGF inhibition.
Pharmacokinetics
Absorption
Baicalin has low oral bioavailability (~2.2% for baicalin itself) due to extensive first-pass metabolism; however, baicalin is hydrolyzed by intestinal bacterial beta-glucuronidase to baicalein (the active aglycone), which is absorbed and achieves higher systemic concentrations. Baicalein Tmax approximately 1-2 hours. The baicalin-to-baicalein bacterial conversion is critical for oral bioavailability and varies with gut microbiome composition.
Distribution
Baicalein: plasma protein binding approximately 90%. Distributes to liver, kidney, brain, and lung. CNS penetration confirmed in rodent models for baicalein and oroxylin A, consistent with neuroprotective and anxiolytic effects [5].
Metabolism
Absorbed baicalein undergoes hepatic reconjugation to baicalin glucuronide and baicalein sulfate via UGT1A and SULT enzymes. Enterohepatic cycling prolongs effective plasma exposure. Baicalin and baicalein inhibit CYP2C9 and CYP3A4 in vitro at higher concentrations [4]. Wogonin undergoes similar conjugation pathways.
Excretion
Baicalein glucuronides and sulfate conjugates excreted in urine and bile. Enterohepatic recirculation prolongs effective half-life. Baicalein plasma t1/2 approximately 3-5 hours with conventional dosing; effective pharmacological t1/2 longer due to recycling. Fecal excretion of intact baicalin also occurs.
Safety and interactions
Drug interactions
Warfarin and CYP2C9 substrates (phenytoin, tolbutamide, celecoxib): CYP2C9 inhibition by baicalin/baicalein may increase plasma concentrations -- monitor INR closely; dose adjustment may be needed [4]. CYP3A4 substrates: moderate inhibition possible at higher doses. Anticoagulants and antiplatelets: additive bleeding risk from antiplatelet activity of baicalein. P-glycoprotein substrates: baicalin inhibits P-gp in vitro -- possible enhanced absorption. Hepatotoxic medications: caution given rare hepatotoxicity reports.
Toxicity
Standardized S. baicalensis root extracts have demonstrated a generally favourable tolerability profile in short-term clinical trials and observational clinical practice; formal long-term safety data from controlled trials are limited. The hepatotoxicity concerns for skullcap supplements in Western markets are primarily attributed to species misidentification or adulteration with Teucrium species rather than authentic S. baicalensis root. LD50 of baicalin in mice is high (>3 g/kg oral). No carcinogenicity in standard assays. Antiplatelet activity at higher doses is the most consistent pharmacological tolerability consideration.
Special precautions
Pregnancy
Insufficient safety data for use during pregnancy. Traditional TCM includes S. baicalensis in some supervised pregnancy formulas, but modern precautionary standards do not support unsupervised self-use during pregnancy. Avoid medicinal-dose supplementation. Evidence basis: no controlled human pregnancy data.
Lactation
Insufficient safety data. Baicalin and baicalein may be excreted in breast milk given lipophilicity. Not recommended during breastfeeding.
Hepatic impairment
Rare hepatotoxicity reports exist (partially confounded by species misidentification). Hepatic metabolism via glucuronidation and CYP enzymes. Use with caution in significant hepatic disease; liver function monitoring recommended.
Renal impairment
Baicalein conjugates excreted renally. No formal pharmacokinetic studies in renal impairment. Use with caution and clinical monitoring in severe renal impairment.
Sources and references
- [1] - Sun Y et al., "Scutellaria baicalensis: pharmacology and clinical applications", Planta Med, 2025, PMID: 40719085 [CRITICAL: this PMID is very high (40M+) — must be independently verified in PubMed before publication; if this PMID is invalid, the foundational modern_application review citation is unsupported]
- [2] - Zhao L et al., "Baicalin and baicalein bioactivities review", Arch Pharm, 2024, PMID: 38849327
- [3] - Dinda B et al., "Therapeutic potential of baicalin", Ann Med, 2024, PMID: 38232757
- [4] - Gao Y et al., "Scutellaria safety and drug interactions", Int J Mol Sci, 2023, PMID: 37298268
- [5] - Li X et al., "Anti-neuroinflammatory effects of Scutellaria baicalensis", Phytomedicine, 2023, PMID: 36655686